These drugs were chosen because each target cancer-specific vulnerabilities such as DNA synthesis (cisplatin, doxorubicin and methotrexate [50–52]), epidermal growth factor receptor (EGFR) (lapatinib) [53] along with the nuclear factor (NF)-κB signaling pathway (bortezomib) known to be constitutively active in many cancer types [54]. Here, EGFR is linked to cancer.